Clinical Marker for Cytoreductive Nephrectomy?
Lorenzo Marconi, MD, FEBU Coimbra, Portugal discusses Clinical Marker for Cytoreductive Nephrectomy?<br />at the Kidney Cancer International Symposium in Dubrovnik 2019.
Author: kidneycancer
Added: 03/29/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 29, 2019 Category: Cancer & Oncology Source Type: podcasts
Fitzpatrick Memorial Lecture - Do we need a new Carmena in the IO era?
John B. Haanen MD PhD gives the Fitzpatrick Memorial Lecture entitled Do we need a new Carmena in the IO era?
Author: kidneycancer
Added: 03/29/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 29, 2019 Category: Cancer & Oncology Source Type: podcasts
Is opt-out the best way to increase organ donation?
As England ’s presumed consent law for 2020 clears parliament, Veronica English, head of medical ethics and human rights at the BMA, say that evidence from Wales and other countries shows that it could increase transplantation rates. But Blair L Sadler, physician and senior adviser to California State Unive rsity, consider such legal changes a distraction lacking strong evidence: they say that public education and trained staff would have a proven impact.
We also hear from Erin Walker, the recipient of 2 liver transplants, about her concerns on families over-ruling donor's wishes.
Read the full deba te, and Erin's comm...
Source: The BMJ Podcast - March 22, 2019 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Is opt-out the best way to increase organ donation?
As England’s presumed consent law for 2020 clears parliament, Veronica English, head of medical ethics and human rights at the BMA, say that evidence from Wales and other countries shows that it could increase transplantation rates. But Blair L Sadler, physician and senior adviser to California State University, consider such legal changes a distraction lacking strong evidence: they say that public education and trained staff would have a proven impact.
We also hear from Erin Walker, the recipient of 2 liver transplants, about her concerns on families over-ruling donor's wishes.
Read the full debate, and Erin's comment...
Source: The BMJ Podcast - March 22, 2019 Category: General Medicine Authors: BMJ Group Source Type: podcasts
The Challenges Using Biomarkers For Treatment Selection In Bladder Cancer
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Challenges Using Biomarkers For Treatment Selection In Bladder Cancer. ...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
The Role Of Checkpoint Inhibitors In Bladder Cancer
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Role Of Checkpoint Inhibitors In Bladder Cancer. At The 2019 Genitourin...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Molecular Characterization & Subtyping Data In Bladder Cancer
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Molecular Characterization & Subtyping Data In Bladder Cancer. At The 2019 ...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
The Latest In Screening For High-Risk Asymptomatic Bladder Cancer
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Latest In Screening For High-Risk Asymptomatic Bladder Cancer. At The 2...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Outcomes Of KEYNOTE 057 In High-Risk Non-Muscle-Invasive Bladder Cancer
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Outcomes Of KEYNOTE 057 In High-Risk Non-Muscle-Invasive Bladder Cancer. At...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Phase 2 STREAM Study In Pre-Metastatic Prostate Cancer
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Phase 2 STREAM Study In Pre-Metastatic Prostate Cancer. At The 2019 Genitourinary...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Opinion On Androgen Receptor Inhibitors
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Opinion On Androgen Receptor Inhibitors. At The 2019 Genitourinary Cancers Sympos...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
Overview Of The ARCHES Trial In mHSPC
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Overview Of The ARCHES Trial In mHSPC. At The 2019 Genitourinary Cancers Symposiu...
Author: obr
Added: 03/20/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 20, 2019 Category: Cancer & Oncology Source Type: podcasts
FDA Drug Safety Podcast: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease
Listen to an audio podcast of the September 21, 2017 FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. Ocaliva is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death. The recommended dosing and monitoring for patients on Ocaliva are described in the current drug label. We are working with the drug manufacturer, Intercept Pharmaceuticals, to address these safety concerns. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
